Watch for Patients on the Parkinson’s Med Nourianz
February 2020
Istradefylline (Nourianz, NUR-ee-anz) will be the first NON-dopaminergic “adenosine antagonist” for Parkinson’s disease...
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote